Allergan plc (NYSE:AGN) declared a quarterly dividend on Friday, October 25th, RTT News reports. Shareholders of record on Wednesday, November 13th will be paid a dividend of 0.74 per share on Friday, December 13th. This represents a $2.96 dividend on an annualized basis and a yield of 1.63%. The ex-dividend date of this dividend is Tuesday, November 12th.
Shares of NYSE:AGN opened at $181.28 on Friday. Allergan has a fifty-two week low of $114.27 and a fifty-two week high of $181.45. The business has a 50-day simple moving average of $171.62 and a two-hundred day simple moving average of $155.71. The company has a debt-to-equity ratio of 0.39, a quick ratio of 0.91 and a current ratio of 1.67. The firm has a market cap of $58.54 billion, a price-to-earnings ratio of 10.86, a price-to-earnings-growth ratio of 2.11 and a beta of 1.66.
Allergan (NYSE:AGN) last issued its earnings results on Tuesday, November 5th. The company reported $4.25 earnings per share for the quarter, hitting the Zacks’ consensus estimate of $4.25. Allergan had a positive return on equity of 9.08% and a negative net margin of 58.50%. The business had revenue of $4.03 billion during the quarter, compared to analyst estimates of $3.88 billion. During the same quarter in the previous year, the firm earned $4.25 EPS. Allergan’s revenue was up 2.9% on a year-over-year basis. As a group, research analysts predict that Allergan will post 16.7 earnings per share for the current year.
Allergan plc, a pharmaceutical company, develops, manufactures, and commercializes branded pharmaceutical, device, biologic, surgical, and regenerative medicine products worldwide. The company operates in three segments: US Specialized Therapeutics, US General Medicine, and International. It offers a portfolio of products in various therapeutic areas, including medical aesthetics and dermatology, eye care, neuroscience, urology, gastrointestinal, women's health, and anti-infective therapeutic products.
Featured Article: What strategies should day traders use to execute a trade?
Receive News & Ratings for Allergan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan and related companies with MarketBeat.com's FREE daily email newsletter.